FORE Biotherapeutics Earns Breakthrough Therapy Designation for Plixorafenib FORE Biotherapeutics, a registration-stage biopharmaceutical company focused on developing precision therapies for cancer, has announced a significant regulatory milestone for its lead investigational therapy. The U.S. Food and Drug Administration has granted…
Strategic Move to Attract and Retain Talent in the Biotech Sector What does it take to attract top talent in the highly competitive biotech industry? Sensei Biotherapeutics, Inc. a clinical-stage biotechnology company focused on developing next-generation therapeutics for cancer patients,…
Atara Biotherapeutics Secures Flexibility for Tabelecleucel Development Why is the timing of milestone payments crucial for biotech companies? Atara Biotherapeutics, Inc. a leader in T-cell immunotherapy, has secured an extension on a significant milestone payment, providing the company with more…
Sonoma Biotherapeutics Announces Leadership Transition as Stephen Dilly, MBBS, PhD, Becomes President and CEO; Co-founder Jeff Bluestone, PhD, Assumes Advisory Role Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company advancing engineered regulatory T-cell (Treg) therapies for autoimmune and inflammatory diseases, announced…
Genetix Biotherapeutics to Highlight U.S. Gene Therapy Implementation and Patient Experience Data at ASH 2025 Genetix Biotherapeutics Inc. announced that an analysis of recent patient experience data from the U.S. commercial implementation of its landmark gene therapies LYFGENIA™ and ZYNTEGLO™…
Transforming Autoimmune and Inflammatory Disease Therapies WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly congratulates Dr. Fred Ramsdell, PhD, co-founder and Chair of the Scientific Advisory Board of its client Sonoma Biotherapeutics, on being…
WuXi Biologics Applauds Sonoma Biotherapeutics Co-Founder Dr. Fred Ramsdell on Receiving the 2025 Nobel Prize in Physiology or Medicine WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly congratulated Fred Ramsdell, PhD, co-founder and Chair…
Sonoma Biotherapeutics Co-Founder Fred Ramsdell Awarded 2025 Nobel Prize in Physiology or Medicine for Pioneering FOXP3 Discovery and Advancing Treg Immunotherapy Sonoma Biotherapeutics, Inc., a leading clinical-stage biotechnology company focused on developing engineered regulatory T cell (Treg) therapies for autoimmune…
Salubris Biotherapeutics Announces Positive Interim Data from Phase 2 Trial of JK07 in Heart Failure Salubris Biotherapeutics a clinical-stage biotechnology company focused on developing innovative biologic therapies, has announced promising interim data from its Phase 2 clinical trial of JK07…
Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company focused on developing innovative biologic therapeutics, announced today that it has received approval from the European Medicines Agency (EMA) to commence a Phase 1 clinical trial of JK06 in various solid tumors…
Genexine (KOSDAQ: 095700), a Korean clinical-stage biopharmaceutical firm dedicated to developing innovative biologics for critical medical needs, has announced a merger with EPD Biotherapeutics (referred to as ‘EPD Bio’), a pioneer in targeted protein degradation (TPD) bioPROTAC platform technology. This…
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, and Pierre Fabre Laboratories, a global player in oncology and responsible for worldwide…